Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2008-12-04
2010-10-12
Cheu, Jacob (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007200, C435S007910, C435S007920
Reexamination Certificate
active
07811776
ABSTRACT:
Described herein are methods of diagnosing lymphangioleiomyomatosis (LAM) that permits differentiating LAM from another lung disorder. Methods of treatment are also provided.
REFERENCES:
patent: 6383484 (2002-05-01), Achen et al.
patent: 7410639 (2008-08-01), Achen et al.
patent: WO-98/07832 (1998-02-01), None
patent: WO-2005/087177 (2005-09-01), None
Achen et al., Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4),Proc. Natl. Acad. Sci. USA, 95: 548-53 (1998).
Berstein et al., How common are renal angiomyolipomas in patients with pulmonary lymphangiomyomatosis?Am. J. Respir. Crit. Care. Med., 152: 2138-2143 (1995).
Byrum, Shellie; The LAM Foundation, Research sheds light on previously untreatable lung disease, Medical News Today News Article, www.medicalnewstoday.com, dated Jan. 11, 2008.
Carsillo et al., Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis,Proc. Natl. Acad. Sci. USA. 97: 6085-90 (2000).
Faul et al., Thoracic lymphangiomas, lymphangiectasis, lymphangiomatosis, and lymphatic dysplasia syndrome,Am. J. Crit. Care Med. 161: 1037-46 (2000).
Johnson et al., Lymphangioleiomyomatosis,Eur. Respir. J. 27: 1056-65 (2006).
Juvet et al., Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans,Am. J. Respir. Cell. Mol. Biol. 36: 398-408 (2007).
McCormack et al., Lymphangioleiomyomatosis: A clinical update,Chest, 133: 507-16 (2008).
Ryu et al., Cystic and cavitary lung disease: Focal and diffuse,Mayo Clin. Proc. 78: 744-52 (2003).
Seyama et al., Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis,Lymphat. Res. Biol. 4: 143-52 (2006).
Stacker et al., Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers,J. Biol. Chem. 247: 32127-36 (1999).
Young et al., Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis,N. Engl. J. Med. 358: 199-200 (2008).
Young et al., Serum VEGF-D as a Diagnostic Test for Lymphangioleiomyomatosis (LAM), Pulmonary, Critical Care, and Sleep Medicine, Cincinnati Children's Hospital Medical Center,Am. J. Respir. Crit. Care Med. 177: Poster to abstract A48 (2008).
Young et al., Lymphangioleiomyomatosis/Thematic Post Session, Serum VEGF-D as a Diagnostic Test for Lymphangioleiomyomatosis (LAM),Am. J. Respir. Crit. Care Med. 177: Abstracts issue: A130 (2008).
McCormack Francis X.
Young Lisa R.
Cheu Jacob
Children's Hospital Medical Center
Marshall & Gerstein & Borun LLP
University of Cincinnati
LandOfFree
Use of VEGF-D in the diagnosis of lymphangioleiomyomatosis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of VEGF-D in the diagnosis of lymphangioleiomyomatosis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of VEGF-D in the diagnosis of lymphangioleiomyomatosis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4178062